share_log

Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4

Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4

Ascendiant Capital維持對Biolase的買入,將目標股價下調至4美元
Moomoo 24/7 ·  04/01 05:40

Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.

Ascendiant Capital分析師愛德華·胡維持Biolase(納斯達克股票代碼:BIOL)的買入,並將目標股價從15美元下調至4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論